Strong biological evaluation strategy starts before testing, not after reviewer questions appear.
The most reliable ISO 10993 programs begin with complete material understanding, correct contact classification, and a disciplined review of existing evidence before anyone decides which tests to run or waive.
A biological evaluation strategy is the logic that connects your device design, materials, risk profile, and regulatory pathway to an endpoint-by-endpoint evaluation plan. When that logic is weak, the BEP becomes a checklist and the BER becomes a defensive rewrite.
Step 1: Identify the Full Material Story
Biological evaluation starts with complete material identification. That includes the obvious patient-contacting materials, but also adhesives, coatings, colorants, processing aids, sterilization residuals, and packaging interactions when relevant.
- Supplier declarations: collect current material specifications, compliance statements, and processing details.
- Construction mapping: identify which materials contact the patient directly, indirectly, or not at all.
- Version control: note any formulation, supplier, or process changes versus previous device versions.
- Residual risk inputs: flag anything that may affect extractables, leachables, or surface response.
Step 2: Get Contact Classification Right
Correct contact classification under ISO 10993-1 is foundational. Surface devices, externally communicating devices, and implants do not trigger the same evaluation logic, and neither do limited, prolonged, and permanent contact durations.
Misclassification early in the process almost always creates avoidable rework later. It changes which endpoints are assessed, how existing data is interpreted, and how defensible a waiver strategy will be.
Step 3: Review Existing Evidence Before Planning New Testing
ISO 10993 is not a “run every test” framework. The right question is whether existing evidence is sufficient for each endpoint. That evidence can include prior testing, literature on comparable materials, supplier data, chemistry information, and clinical use history.
- Literature review: look for material-specific and device-relevant evidence, not generic marketing claims.
- Prior test data: assess relevance to the current design, sterilization, and manufacturing state.
- Chemical characterization: use it to support endpoint decisions where extractables or leachables matter.
- Equivalence logic: document carefully when relying on predicate or platform evidence.
Step 4: Decide Where TRA Is Needed
Complex polymers, coatings, residual processing chemistry, and extractables concerns often require toxicological risk assessment under ISO 10993-17 and ISO 10993-18. A good strategy identifies this early rather than treating TRA as an afterthought when a reviewer asks for it.
TRA becomes especially important when testing is being reduced, waived, or reframed based on chemistry data. In those cases, the toxicological argument is often what makes the overall biological evaluation defensible.
Step 5: Translate the Logic Into a Real BEP
The BEP should make the strategy legible. It should show the device context, the contact classification, the applicable endpoints, and the evaluation path for each endpoint: existing evidence, chemistry, new testing, or scientifically justified waiver.
A strong BEP also makes visible where uncertainties remain and what additional work is actually required before final conclusions can be written.
Step 6: Use the BER to Close the Loop
The BER is not where strategy is invented. It is where the planned logic is executed, the evidence is evaluated, and endpoint conclusions are documented. The stronger the earlier strategy, the cleaner and more persuasive the BER becomes.
If your endpoint plan cannot be explained clearly before testing begins, it will be much harder to defend after a notified body or FDA reviewer starts asking why certain endpoints were tested, waived, or ignored.
Need help shaping your biological evaluation strategy before it turns into a review problem?
Discuss Your Project Back to Resources